Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  INDONESIA STOCK EXCHANGE  >  Kalbe Farma Tbk PT    KLBF   ID1000125107

KALBE FARMA TBK PT

(KLBF)
  Report
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Kalbe Farma Tbk PT : Disclosure of Information - Establishment of a Subsidiary, Kalbe Lanka (Pvt) Ltd.

share with twitter share with LinkedIn share with facebook
share via e-mail
10/28/2019 | 03:32am EST

In compliance with Indonesia Financial Services Authority Regulation No. 31/POJK.04/2015 dated December 16, 2015 regarding Disclosure of Information or Material Facts by the Issuer or a Listed Company, the Company hereby announces that :

a. Kalbe International Ltd ('KI') and PT Dankos Farma ('DF') are companies which their shares are 100% owned by the Company, both directly or indirectly;

b. On October 24, 2019, KI and DF agreed to establish a new company called Kalbe Lanka (Pvt) Ltd. the total paid up capital and issued capital is US$ 600,000 with a share of investment ownership of KI was US$ 594,000 (99%) and DF was US$ 6,000 (1%).

Disclaimer

PT Kalbe Farma Tbk published this content on 28 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2019 08:31:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on KALBE FARMA TBK PT
02/05KALBE FARMA TBK PT : Change of Corporate Secretary of PT Kalbe Farma Tbk
PU
2019KALBE FARMA TBK PT : Disclosure of Information - Increased in Issued and Paid in..
PU
2019KALBE FARMA TBK PT : Disclosure of Information - Increased in Issued and Paid in..
PU
2019KALBE FARMA TBK PT : Growth Improvement in Sales and Net Income
PU
2019Indonesia hikes state health insurer's premiums to plug deficit
RE
2019KALBE FARMA TBK PT : Disclosure of Information - Establishment of a Subsidiary, ..
PU
2019KALBE FARMA TBK PT : Will Participate In CPhI In Frankfurt
PU
2019KALBE FARMA TBK PT : Commemorates World Hepatitis Day
PU
2019KALBE FARMA TBK PT : Genexine Biologics Enters Into an Exclusive Licensing of Im..
PU
2019KALBE FARMA TBK PT : Maintain Better Company Performance
PU
More news
Financials (IDR)
Sales 2019 22 845 B
EBIT 2019 3 525 B
Net income 2019 2 665 B
Finance 2019 2 807 B
Yield 2019 1,86%
P/E ratio 2019 25,0x
P/E ratio 2020 23,5x
EV / Sales2019 2 914x
EV / Sales2020 2 715x
Capitalization 66 563 B
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 1 740,83  IDR
Last Close Price 1 420,00  IDR
Spread / Highest target 40,8%
Spread / Average Target 22,6%
Spread / Lowest Target -15,5%
EPS Revisions
Managers
NameTitle
Vidjongtius President Director
Bernadette Ruth Setiady President Commissioner
Dino Bramanto Head-Corporate Information Technology & System
Santoso Oen Commissioner
Ferdinand Aryanto Commissioner
Sector and Competitors
1st jan.Capitalization (M$)
KALBE FARMA TBK PT4 906
JOHNSON & JOHNSON2.24%392 415
ROCHE HOLDING AG10.05%303 192
NOVARTIS3.81%220 641
MERCK AND COMPANY-9.84%208 771
PFIZER-7.30%200 501